Hisamitsu Pharmaceutical Co. Inc
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP X… Read more
Hisamitsu Pharmaceutical Co. Inc (HPX) - Net Assets
Latest net assets as of August 2024: €275.92 Billion EUR
Based on the latest financial reports, Hisamitsu Pharmaceutical Co. Inc (HPX) has net assets worth €275.92 Billion EUR as of August 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€350.48 Billion) and total liabilities (€74.55 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €275.92 Billion |
| % of Total Assets | 78.73% |
| Annual Growth Rate | 3.26% |
| 5-Year Change | 10.09% |
| 10-Year Change | 23.58% |
| Growth Volatility | 3.61 |
Hisamitsu Pharmaceutical Co. Inc - Net Assets Trend (2014–2025)
This chart illustrates how Hisamitsu Pharmaceutical Co. Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hisamitsu Pharmaceutical Co. Inc (2014–2025)
The table below shows the annual net assets of Hisamitsu Pharmaceutical Co. Inc from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-02-28 | €279.40 Billion | +4.62% |
| 2024-02-29 | €267.08 Billion | +3.36% |
| 2023-02-28 | €258.40 Billion | +1.38% |
| 2022-02-28 | €254.88 Billion | +0.42% |
| 2021-02-28 | €253.81 Billion | +1.22% |
| 2020-02-29 | €250.74 Billion | +1.04% |
| 2019-02-28 | €248.16 Billion | +1.20% |
| 2018-02-28 | €245.22 Billion | +6.99% |
| 2017-02-28 | €229.20 Billion | +1.38% |
| 2016-02-29 | €226.09 Billion | +1.82% |
| 2015-02-28 | €222.05 Billion | +13.12% |
| 2014-02-28 | €196.31 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hisamitsu Pharmaceutical Co. Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 37.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (February 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €257.88 Billion | 93.16% |
| Other Components | €18.94 Billion | 6.84% |
| Total Equity | €276.82 Billion | 100.00% |
Hisamitsu Pharmaceutical Co. Inc Competitors by Market Cap
The table below lists competitors of Hisamitsu Pharmaceutical Co. Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hellenic Telec
LSE:0FIZ
|
$2.09 Billion |
|
Dave Inc
NASDAQ:DAVE
|
$2.09 Billion |
|
Enka Insaat ve Sanayi A.S
OTCGREY:EKIVF
|
$2.10 Billion |
|
Dr Ing hcF Porsche AG
F:P911
|
$2.10 Billion |
|
ComfortDelGro Corporation Limited
STU:VZ1
|
$2.09 Billion |
|
InnoDisk
TWO:5289
|
$2.09 Billion |
|
Grupa KĘTY SA
WAR:KTY
|
$2.09 Billion |
|
Adamas Trust, Inc.
NASDAQ:ADAMG
|
$2.09 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hisamitsu Pharmaceutical Co. Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 264,871,000,000 to 276,822,000,000, a change of 11,951,000,000 (4.5%).
- Net income of 21,758,000,000 contributed positively to equity growth.
- Dividend payments of 6,519,000,000 reduced retained earnings.
- Share repurchases of 10,554,000,000 reduced equity.
- Other factors increased equity by 7,266,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €21.76 Billion | +7.86% |
| Dividends Paid | €6.52 Billion | -2.35% |
| Share Repurchases | €10.55 Billion | -3.81% |
| Other Changes | €7.27 Billion | +2.62% |
| Total Change | €- | 4.51% |
Book Value vs Market Value Analysis
This analysis compares Hisamitsu Pharmaceutical Co. Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-02-28 | €2726.39 | €31.80 | x |
| 2018-02-28 | €2916.37 | €31.80 | x |
| 2019-02-28 | €2986.33 | €31.80 | x |
| 2020-02-29 | €3052.41 | €31.80 | x |
| 2021-02-28 | €3086.77 | €31.80 | x |
| 2022-02-28 | €3174.98 | €31.80 | x |
| 2023-02-28 | €3297.50 | €31.80 | x |
| 2024-02-29 | €3496.96 | €31.80 | x |
| 2025-02-28 | €3795.48 | €31.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hisamitsu Pharmaceutical Co. Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.86%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.95%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.24x
- Recent ROE (7.86%) is above the historical average (7.05%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 10.93% | 14.18% | 0.60x | 1.29x | €1.81 Billion |
| 2015 | 8.50% | 11.98% | 0.55x | 1.29x | €-3.32 Billion |
| 2016 | 7.90% | 10.99% | 0.57x | 1.27x | €-4.73 Billion |
| 2017 | 8.94% | 13.98% | 0.52x | 1.22x | €-2.42 Billion |
| 2018 | 7.84% | 12.93% | 0.49x | 1.23x | €-5.28 Billion |
| 2019 | 7.78% | 13.39% | 0.48x | 1.21x | €-5.48 Billion |
| 2020 | 7.50% | 13.26% | 0.46x | 1.23x | €-6.23 Billion |
| 2021 | 3.67% | 8.08% | 0.38x | 1.19x | €-15.98 Billion |
| 2022 | 3.81% | 8.04% | 0.40x | 1.20x | €-15.66 Billion |
| 2023 | 4.58% | 9.15% | 0.41x | 1.22x | €-13.89 Billion |
| 2024 | 5.27% | 9.86% | 0.43x | 1.24x | €-12.52 Billion |
| 2025 | 7.86% | 13.95% | 0.45x | 1.24x | €-5.92 Billion |
Industry Comparison
This section compares Hisamitsu Pharmaceutical Co. Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hisamitsu Pharmaceutical Co. Inc (HPX) | €275.92 Billion | 10.93% | 0.27x | $2.09 Billion |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |